Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2014 · 10-Q
Revenue$14.61M$14.61M−8.8% vs Q3 2013 Net Income-$20.28M-$20.28MN/M vs Q3 2013 EPS Diluted-$0.16-$0.16N/M vs Q3 2013 Gross Profit$4,476,000−52.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$13,183,000N/M Free Cash Flowderived-$13,554,000N/M Margins · derivedGross margin30.6%−27.7 pt vs Q3 2013
Operating margin-130.3%−14.8 pt vs Q3 2013
Net margin-138.8%−18.4 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 10, 2014 · 41 d after period end